Combination therapy with TNFR-Fc and CTLA4-FasL using the recombinant adeno-associated virus potently suppresses adjuvant-induced arthritis in rats

Verfasser / Beitragende:
[Fang Wang, Jiyun Yu, Yu Wang, Yunbo Jiang, Ning Guo, Wei Zhang]
Ort, Verlag, Jahr:
2015
Enthalten in:
Applied Microbiology and Biotechnology, 99/15(2015-08-01), 6327-6337
Format:
Artikel (online)
ID: 605506523
LEADER caa a22 4500
001 605506523
003 CHVBK
005 20210128100627.0
007 cr unu---uuuuu
008 210128e20150801xx s 000 0 eng
024 7 0 |a 10.1007/s00253-015-6459-7  |2 doi 
035 |a (NATIONALLICENCE)springer-10.1007/s00253-015-6459-7 
245 0 0 |a Combination therapy with TNFR-Fc and CTLA4-FasL using the recombinant adeno-associated virus potently suppresses adjuvant-induced arthritis in rats  |h [Elektronische Daten]  |c [Fang Wang, Jiyun Yu, Yu Wang, Yunbo Jiang, Ning Guo, Wei Zhang] 
520 3 |a The complexity of rheumatoid arthritis (RA) pathogenesis makes combined blockade of key pathogenic factors an attractive therapeutic strategy. We have previously reported a novel recombinant adeno-associated virus (AAV) vector, AAV.TFCF, which mediates separate coexpression of TNFα antagonist TNFR-Fc and T cell antagonist CTLA4-FasL both in vitro and in vivo (the injected joints). The purpose of this study was to examine the efficacy of TNFR-Fc/CTLA4-FasL combination therapy mediated by AAV.TFCF in experimental model of RA. Adjuvant-induced arthritis (AIA) was induced in Lewis rats, and the recombinant AAV.TFCF was injected into rat ankle joints. AAV vector encoding CTLA4-FasL (AAV.CTFA) or TNFR-Fc (AAV.TRFC) was used as the monotherapy control, and an AAV vector mediating the expression of enhanced green fluorescent protein (AAV.EGFP) was used as the negative control. The combination treatment mediated by AAV.TFCF demonstrated a more effective suppression of AIA compared with those monotherapy controls, as reflected in the clinical and histological observations. The synergistic anti-inflammatory effect of TNFR-Fc combining with CTLA4-FasL was proved to be associated with the greater reductions of inflammatory CD4+ T cell infiltration and proinflammatory cytokine TNFα level in the arthritic joints. In addition, the combination therapy was found to be able to increase the frequency of CD4 + CD25 + FoxP3+ regulatory T cell population in rat draining lymph nodes and suppress splenic inflammatory responses. These results suggest that combination treatment with TNFR-Fc and CTLA4-FasL may achieve superior efficacy in suppressing RA, and using this novel recombinant AAV.TFCF to obtain the combined counteraction of both pathogenic T cells and the key proinflammatory cytokine TNFα may provide a more effective and desirable strategy for treatment of RA. 
540 |a Springer-Verlag Berlin Heidelberg, 2015 
690 7 |a Rheumatoid arthritis  |2 nationallicence 
690 7 |a Combination therapy  |2 nationallicence 
690 7 |a CTLA4-FasL  |2 nationallicence 
690 7 |a TNFR-Fc  |2 nationallicence 
700 1 |a Wang  |D Fang  |u Department of Translational Medicine, Beijing Institute of Basic Medical Sciences, 27 Taiping Road, 100850, Beijing, China  |4 aut 
700 1 |a Yu  |D Jiyun  |u Department of Translational Medicine, Beijing Institute of Basic Medical Sciences, 27 Taiping Road, 100850, Beijing, China  |4 aut 
700 1 |a Wang  |D Yu  |u Department of Translational Medicine, Beijing Institute of Basic Medical Sciences, 27 Taiping Road, 100850, Beijing, China  |4 aut 
700 1 |a Jiang  |D Yunbo  |u Department of Translational Medicine, Beijing Institute of Basic Medical Sciences, 27 Taiping Road, 100850, Beijing, China  |4 aut 
700 1 |a Guo  |D Ning  |u Department of Translational Medicine, Beijing Institute of Basic Medical Sciences, 27 Taiping Road, 100850, Beijing, China  |4 aut 
700 1 |a Zhang  |D Wei  |u Department of Translational Medicine, Beijing Institute of Basic Medical Sciences, 27 Taiping Road, 100850, Beijing, China  |4 aut 
773 0 |t Applied Microbiology and Biotechnology  |d Springer Berlin Heidelberg  |g 99/15(2015-08-01), 6327-6337  |x 0175-7598  |q 99:15<6327  |1 2015  |2 99  |o 253 
856 4 0 |u https://doi.org/10.1007/s00253-015-6459-7  |q text/html  |z Onlinezugriff via DOI 
898 |a BK010053  |b XK010053  |c XK010000 
900 7 |a Metadata rights reserved  |b Springer special CC-BY-NC licence  |2 nationallicence 
908 |D 1  |a research-article  |2 jats 
949 |B NATIONALLICENCE  |F NATIONALLICENCE  |b NL-springer 
950 |B NATIONALLICENCE  |P 856  |E 40  |u https://doi.org/10.1007/s00253-015-6459-7  |q text/html  |z Onlinezugriff via DOI 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Wang  |D Fang  |u Department of Translational Medicine, Beijing Institute of Basic Medical Sciences, 27 Taiping Road, 100850, Beijing, China  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Yu  |D Jiyun  |u Department of Translational Medicine, Beijing Institute of Basic Medical Sciences, 27 Taiping Road, 100850, Beijing, China  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Wang  |D Yu  |u Department of Translational Medicine, Beijing Institute of Basic Medical Sciences, 27 Taiping Road, 100850, Beijing, China  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Jiang  |D Yunbo  |u Department of Translational Medicine, Beijing Institute of Basic Medical Sciences, 27 Taiping Road, 100850, Beijing, China  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Guo  |D Ning  |u Department of Translational Medicine, Beijing Institute of Basic Medical Sciences, 27 Taiping Road, 100850, Beijing, China  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Zhang  |D Wei  |u Department of Translational Medicine, Beijing Institute of Basic Medical Sciences, 27 Taiping Road, 100850, Beijing, China  |4 aut 
950 |B NATIONALLICENCE  |P 773  |E 0-  |t Applied Microbiology and Biotechnology  |d Springer Berlin Heidelberg  |g 99/15(2015-08-01), 6327-6337  |x 0175-7598  |q 99:15<6327  |1 2015  |2 99  |o 253